Equities

Clinica las Condes SA

LASCONDES:SGO

Clinica las Condes SA

Actions
Health CareHealth Care Providers
  • Price (CLP)12,200.00
  • Today's Change0.00 / 0.00%
  • Shares traded258.00
  • 1 Year change-46.61%
  • Beta0.3505
Data delayed at least 20 minutes, as of Sep 17 2024 15:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CLPIncome statement in CLPView more

Year on year Clinica las Condes SA's revenues fell -22.20% from 259.99bn to 202.26bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 4.05bn to a loss of 3.40bn.
Gross margin30.78%
Net profit margin-1.52%
Operating margin4.31%
Return on assets-0.53%
Return on equity-1.11%
Return on investment-0.63%
More ▼

Cash flow in CLPView more

In 2023, cash reserves at Clinica las Condes SA fell by 14.71bn. However, the company earned 13.59bn from its operations for a Cash Flow Margin of 6.72%. In addition the company used 5.60bn on investing activities and also paid 22.70bn in financing cash flows.
Cash flow per share1,078.54
Price/Cash flow per share15.06
Book value per share31,741.15
Tangible book value per share31,068.37
More ▼

Balance sheet in CLPView more

Clinica las Condes SA has a Debt to Total Capital ratio of 41.86%, a lower figure than the previous year's 61.72%.
Current ratio1.56
Quick ratio1.53
Total debt/total equity0.7199
Total debt/total capital0.4186
More ▼

Growth rates in CLP

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -78.03% and -184.04%, respectively.
Div yield(5 year avg)1.39%
Div growth rate (5 year)--
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-140.14
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.